메뉴 건너뛰기




Volumn 24, Issue 5, 2013, Pages 1231-1238

Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer

Author keywords

Automated analysis; Breast cancer; Circulating tumor cells; Her 2; Quantitative assessment

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

EID: 84874667197     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds625     Document Type: Article
Times cited : (59)

References (30)
  • 1
    • 0022399581 scopus 로고
    • Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
    • Coussens L, Yangfeng TL, Liao YC et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230: 1132-1139.
    • (1985) Science , vol.230 , pp. 1132-1139
    • Coussens, L.1    Yangfeng, T.L.2    Liao, Y.C.3
  • 2
    • 0035869407 scopus 로고    scopus 로고
    • Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    • Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
    • (2001) N Engl J Med , vol.344 , pp. 783-792
    • Slamon, D.J.1    Leyland-Jones, B.2    Shak, S.3
  • 3
    • 33847147313 scopus 로고    scopus 로고
    • American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
    • Wolff AC, Hammond MEH, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
    • (2007) J Clin Oncol , vol.25 , pp. 118-145
    • Wolff, A.C.1    Hammond, M.E.H.2    Schwartz, J.N.3
  • 4
    • 79953311677 scopus 로고    scopus 로고
    • HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care
    • Fabi A, Di Benedetto A, Metro G et al. HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. Clin Cancer Res 2011; 17: 2055-2064.
    • (2011) Clin Cancer Res , vol.17 , pp. 2055-2064
    • Fabi, A.1    Di Benedetto, A.2    Metro, G.3
  • 5
    • 69849090104 scopus 로고    scopus 로고
    • Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?
    • Simmons C, Miller N, Geddie W et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?. Ann Oncol 2009; 20: 1499-1504.
    • (2009) Ann Oncol , vol.20 , pp. 1499-1504
    • Simmons, C.1    Miller, N.2    Geddie, W.3
  • 6
    • 84874651590 scopus 로고    scopus 로고
    • Translating metastasis-related biomarkers to the clinic, progress and pitfalls
    • in press
    • Bidard FC PJ, Soria JC, Thiery JP. Translating metastasis-related biomarkers to the clinic, progress and pitfalls. Nat Rev Clin Oncol 2013; in press.
    • (2013) Nat Rev Clin Oncol
    • Bidard, F.C.P.J.1    Soria, J.C.2    Thiery, J.P.3
  • 7
    • 4143094988 scopus 로고    scopus 로고
    • Circulating tumor cells, disease progression, and survival in metastatic breast cancer
    • Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-791.
    • (2004) N Engl J Med , vol.351 , pp. 781-791
    • Cristofanilli, M.1    Budd, G.T.2    Ellis, M.J.3
  • 8
    • 70449713638 scopus 로고    scopus 로고
    • Circulating Tumor Cells: A Useful Predictor of Treatment Efficacy in Metastatic Breast Cancer
    • Liu MC, Shields PG, Warren RD et al. Circulating Tumor Cells: A Useful Predictor of Treatment Efficacy in Metastatic Breast Cancer. J Clin Oncol 2009; 27: 5153-5159.
    • (2009) J Clin Oncol , vol.27 , pp. 5153-5159
    • Liu, M.C.1    Shields, P.G.2    Warren, R.D.3
  • 9
    • 77955514306 scopus 로고    scopus 로고
    • Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer
    • Nakamura S, Yagata H, Ohno S et al. Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer 2010; 17: 199-204.
    • (2010) Breast Cancer , vol.17 , pp. 199-204
    • Nakamura, S.1    Yagata, H.2    Ohno, S.3
  • 10
    • 43049110616 scopus 로고    scopus 로고
    • Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications
    • Nole F, Munzone E, Zorzino L et al. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol 2008; 19: 891-897.
    • (2008) Ann Oncol , vol.19 , pp. 891-897
    • Nole, F.1    Munzone, E.2    Zorzino, L.3
  • 11
    • 84857613654 scopus 로고    scopus 로고
    • High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients
    • Pierga JY, Hajage D, Bachelot T et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol 2012; 23: 618-624.
    • (2012) Ann Oncol , vol.23 , pp. 618-624
    • Pierga, J.Y.1    Hajage, D.2    Bachelot, T.3
  • 12
    • 0036834995 scopus 로고    scopus 로고
    • Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer
    • Hayes DF, Walker TM, Singh B et al. Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. Int J Oncol 2002; 21: 1111-1117.
    • (2002) Int J Oncol , vol.21 , pp. 1111-1117
    • Hayes, D.F.1    Walker, T.M.2    Singh, B.3
  • 13
    • 33751215245 scopus 로고    scopus 로고
    • uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues
    • Meng S, Tripathy D, Shete S et al. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci USA 2006; 103: 17361-17365.
    • (2006) Proc Natl Acad Sci USA , vol.103 , pp. 17361-17365
    • Meng, S.1    Tripathy, D.2    Shete, S.3
  • 14
    • 3042552362 scopus 로고    scopus 로고
    • HER-2 gene amplification can be acquired as breast cancer progresses
    • Meng SD, Tripathy D, Shete S et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 2004; 101: 9393-9398.
    • (2004) Proc Natl Acad Sci USA , vol.101 , pp. 9393-9398
    • Meng, S.D.1    Tripathy, D.2    Shete, S.3
  • 15
    • 77956132705 scopus 로고    scopus 로고
    • Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy
    • Bidard FC, Mathiot C, Degeorges A et al. Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol 2010; 21: 1765-1771.
    • (2010) Ann Oncol , vol.21 , pp. 1765-1771
    • Bidard, F.C.1    Mathiot, C.2    Degeorges, A.3
  • 16
    • 77955082633 scopus 로고    scopus 로고
    • All circulating EpCAM+CK+CD45-objects predict overall survival in castration-resistant prostate cancer
    • Coumans FAW, Doggen CJM, Attard G et al. All circulating EpCAM+CK+CD45-objects predict overall survival in castration-resistant prostate cancer. Ann Oncol 2010; 21: 1851-1857.
    • (2010) Ann Oncol , vol.21 , pp. 1851-1857
    • Coumans, F.A.W.1    Doggen, C.J.M.2    Attard, G.3
  • 17
    • 79951909396 scopus 로고    scopus 로고
    • External quality assurance of circulating tumor cell enumeration using the CellSearch((R)) system: a feasibility study
    • Kraan J, Sleijfer S, Strijbos MH et al. External quality assurance of circulating tumor cell enumeration using the CellSearch((R)) system: a feasibility study. Cytometry B Clin Cytom 2010; 80B: 112-118.
    • (2010) Cytometry B Clin Cytom , vol.80 B , pp. 112-118
    • Kraan, J.1    Sleijfer, S.2    Strijbos, M.H.3
  • 18
    • 79251548904 scopus 로고    scopus 로고
    • HER2-positive circulating tumor cells in breast cancer
    • Ignatiadis M, Rothe F, Chaboteaux C et al. HER2-positive circulating tumor cells in breast cancer. Plos One 2011; 10(6): e15624.
    • (2011) Plos One , vol.10 , Issue.6
    • Ignatiadis, M.1    Rothe, F.2    Chaboteaux, C.3
  • 19
    • 77951740458 scopus 로고    scopus 로고
    • Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial
    • Riethdorf S, Muller V, Zhang LL et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010; 16: 2634-2645.
    • (2010) Clin Cancer Res , vol.16 , pp. 2634-2645
    • Riethdorf, S.1    Muller, V.2    Zhang, L.L.3
  • 20
    • 84859158912 scopus 로고    scopus 로고
    • Neoadjuvant bevacizumab, trastuzumab and chemotherapy for primary inflammatory HER-2positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study
    • Pierga JY, Petit T, Delozier T et al. Neoadjuvant bevacizumab, trastuzumab and chemotherapy for primary inflammatory HER-2positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. Lancet Oncol 2012; 13: 375-384.
    • (2012) Lancet Oncol , vol.13 , pp. 375-384
    • Pierga, J.Y.1    Petit, T.2    Delozier, T.3
  • 21
    • 84877110619 scopus 로고    scopus 로고
    • Monitoring Circulating Tumor Cells (CTC) and Circulating Endothelial Cells (CEC) during Neoadjuvant Combination of Trastuzumab and Bevacizumab with Chemotherapy in HER2 Overexpressing Inflammatory Breast Cancer (IBC): An Ancillary Study of BEVERLY 2 Multicenter Phase II Trial
    • San Antonio, TX
    • Pierga JY, Bidard FC, Petit T et al. Monitoring Circulating Tumor Cells (CTC) and Circulating Endothelial Cells (CEC) during Neoadjuvant Combination of Trastuzumab and Bevacizumab with Chemotherapy in HER2 Overexpressing Inflammatory Breast Cancer (IBC): An Ancillary Study of BEVERLY 2 Multicenter Phase II Trial. San Antonio, TX: In San Antonio Breast Cancer Symposium, 2010, PD04-PD07.
    • (2010) San Antonio Breast Cancer Symposium
    • Pierga, J.Y.1    Bidard, F.C.2    Petit, T.3
  • 22
    • 18544370747 scopus 로고    scopus 로고
    • A sample preparation and analysis system for identification of circulating tumor cells
    • Kagan M, Howard D, Bendele T et al. A sample preparation and analysis system for identification of circulating tumor cells. J Clin Ligand Assay 2002; 25: 104-110.
    • (2002) J Clin Ligand Assay , vol.25 , pp. 104-110
    • Kagan, M.1    Howard, D.2    Bendele, T.3
  • 23
    • 80455126047 scopus 로고    scopus 로고
    • Automated classification of circulating tumor cells optimized using clinical outcome of castration resistant prostate cancer patients
    • Ligthart ST, Coumans FAW, Attard G et al. Automated classification of circulating tumor cells optimized using clinical outcome of castration resistant prostate cancer patients. PLos One 2011; 6: e27419.
    • (2011) PLos One , vol.6
    • Ligthart, S.T.1    Coumans, F.A.W.2    Attard, G.3
  • 25
    • 84864085607 scopus 로고    scopus 로고
    • Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression
    • Lindstrom LS, Karlsson E, Wilking UM et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012; 30: 2601-2608.
    • (2012) J Clin Oncol , vol.30 , pp. 2601-2608
    • Lindstrom, L.S.1    Karlsson, E.2    Wilking, U.M.3
  • 26
    • 84860356499 scopus 로고    scopus 로고
    • Biomarkers characterization of circulating tumour cells in breast cancer patients
    • Nadal R, Fernandez A, Sanchez-Rovira P et al. Biomarkers characterization of circulating tumour cells in breast cancer patients. Breast Cancer Res. 2012; 14(3): R71.
    • (2012) Breast Cancer Res. , vol.14 , Issue.3
    • Nadal, R.1    Fernandez, A.2    Sanchez-Rovira, P.3
  • 27
    • 77958557955 scopus 로고    scopus 로고
    • Molecular biomarker analyses using circulating tumor cells
    • Punnoose EA, Atwal SK, Spoerke JM et al. Molecular biomarker analyses using circulating tumor cells. Plos One 2010.
    • (2010) Plos One
    • Punnoose, E.A.1    Atwal, S.K.2    Spoerke, J.M.3
  • 28
    • 84857088316 scopus 로고    scopus 로고
    • FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE (TM) platform
    • Mayer JA, Pham T, Wong KL et al. FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE (TM) platform. Cancer Genet 2011; 204: 589-595.
    • (2011) Cancer Genet , vol.204 , pp. 589-595
    • Mayer, J.A.1    Pham, T.2    Wong, K.L.3
  • 30
    • 84878112286 scopus 로고    scopus 로고
    • Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials
    • November 6, [epub ahead of print], doi: 10.1007/s10555-012-9398-0
    • Bidard FC, Fehm T, Ignatiadis M et al. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Met Rev 2013, November 6, [epub ahead of print], doi: 10.1007/s10555-012-9398-0.
    • (2013) Cancer Met Rev
    • Bidard, F.C.1    Fehm, T.2    Ignatiadis, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.